MedTrace Logo

Clinical Trials

NCT03939897 | ACTIVE_NOT_RECRUITING | PHASE1
24 participants

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2020-06-17
Completion:
2023-06-22
Conditions
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Breast Carcinoma
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Hormone Receptor-Positive Breast Carcinoma
  • Recurrent Breast Carcinoma
Interventions
  • DRUG
  • PROCEDURE
Results Available
NCT03935893 | ACTIVE_NOT_RECRUITING | PHASE2
20 participants

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-12-03
Completion:
2037-06-30
Conditions
  • Gastric Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Sarcoma
  • Mesothelioma
  • Neuroendocrine Tumors
  • Squamous Cell Cancer
  • Merkel Cell Carcinoma
  • Mismatch Repair Deficiency
  • Microsatellite Instability
Interventions
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT03914300 | ACTIVE_NOT_RECRUITING | PHASE2
11 participants

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2020-02-10
Completion:
2024-10-17
Conditions
  • Differentiated Thyroid Gland Carcinoma
  • Follicular Variant Thyroid Gland Papillary Carcinoma
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Refractory Differentiated Thyroid Gland Carcinoma
  • Refractory Thyroid Gland Carcinoma
  • Tall Cell Variant Thyroid Gland Papillary Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Oncocytic Carcinoma
  • Thyroid Gland Papillary Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT03907488 | ACTIVE_NOT_RECRUITING | PHASE3
994 participants

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-08-29
Completion:
2024-03-31
Conditions
  • Ann Arbor Stage III Hodgkin Lymphoma
  • Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
  • Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
  • Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Hodgkin Lymphoma
  • Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
  • Classic Hodgkin Lymphoma
  • Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
  • PROCEDURE
  • OTHER
  • RADIATION
  • DRUG
  • BIOLOGICAL
Results Available
NCT03896503 | ACTIVE_NOT_RECRUITING | PHASE2
104 participants

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-12-30
Completion:
2022-12-19
Conditions
  • Extensive Stage Lung Small Cell Carcinoma
  • Extrapulmonary Small Cell Neuroendocrine Carcinoma
  • Limited Stage Lung Small Cell Carcinoma
  • Platinum-Resistant Lung Small Cell Carcinoma
  • Platinum-Sensitive Lung Small Cell Carcinoma
  • Recurrent Lung Small Cell Carcinoma
Interventions
  • PROCEDURE
  • DRUG
Results Available
NCT03872427 | ACTIVE_NOT_RECRUITING | PHASE2
54 participants

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-12-14
Completion:
2023-10-30
Conditions
  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
  • Unresectable Malignant Solid Neoplasm
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
Results Available
NCT03811002 | ACTIVE_NOT_RECRUITING | PHASE3
544 participants

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-07-26
Completion:
2024-04-21
Conditions
  • Limited Stage Lung Small Cell Carcinoma
  • Stage I Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
Interventions
  • RADIATION
  • DRUG
  • PROCEDURE
  • OTHER
Results Available
NCT03712605 | ACTIVE_NOT_RECRUITING | PHASE3
280 participants

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2018-11-15
Completion:
2026-12-31
Conditions
  • Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
  • OTHER
  • PROCEDURE
  • BIOLOGICAL
  • RADIATION
No Results Yet
NCT03698019 | ACTIVE_NOT_RECRUITING | PHASE2
313 participants

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-02-15
Completion:
2022-09-01
Conditions
  • Acral Lentiginous Melanoma
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Mucosal Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
Results Available
NCT03684018 | RECRUITING | PHASE4
30 participants

Two Dose Levels of Privigen in Pediatric CIDP

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2019-02-28
Completion:
2029-12-20
Conditions
  • Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
  • BIOLOGICAL
No Results Yet
NCT03660826 | ACTIVE_NOT_RECRUITING | PHASE2
288 participants

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-01
Start Date:
2018-09-27
Completion:
2024-12-06
Conditions
  • Endometrial Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Endometrioid Adenocarcinoma
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page